SCHEMBL16114149

SCHEMBL16114149

COc1ncc(Cn2cnc(CO)n2)cc1-c1cccc(Cl)c1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 2/20 0.41
HDAC6 Q9UBN7 2/20 0.41
CTSA P10619 2/20 0.40
KDR P35968 1/20 0.39
EPHB4 P54760 1/20 0.39
TEK Q02763 1/20 0.39
PDE4B Q07343 3/20 0.38
CYP19A1 P11511 1/20 0.37
NUDT1 P36639 1/20 0.36
FYN P06241 2/20 0.36
KMT2A Q03164 1/20 0.35
MET P08581 1/20 0.35
AXL P30530 1/20 0.35
MERTK Q12866 1/20 0.35
CNR2 P34972 1/20 0.35
XPO1 O14980 2/20 0.35
FFAR4 Q5NUL3 1/20 0.35
ADORA1 P30542 1/20 0.34
PDE4D Q08499 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16046332 0.92 HDAC1 (0.41) HDAC1HDAC6CTSAKDREPHB4
SCHEMBL16043829 0.87 PDE4B (0.40) HDAC1HDAC6KDREPHB4TEK
SCHEMBL16114418 0.87 HDAC1 (0.40) HDAC1HDAC6KDREPHB4TEK
SCHEMBL16046675 0.86 HDAC1 (0.41) HDAC1HDAC6CTSAKDREPHB4
SCHEMBL16046695 0.86 HDAC1 (0.41) HDAC1HDAC6CTSAKDREPHB4
SCHEMBL16043814 0.85 PDE4B (0.41) HDAC1HDAC6CTSAKDREPHB4
SCHEMBL16044644 0.85 HDAC1 (0.41) HDAC1HDAC6CTSAKDREPHB4
SCHEMBL16114261 0.84 CTSA (0.41) CTSAKDREPHB4TEKPDE4B
SCHEMBL16075840 0.84 HDAC1 (0.41) HDAC1HDAC6CTSAKDREPHB4
SCHEMBL16113522 0.84 CTSA (0.45) HDAC1HDAC6CTSAKDREPHB4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3345902-B1 SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS DART NEUROSCIENCE CAYMAN LTD (KY) 2019-10-30 EP claimed
EP-3345902-A1 SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS Dart NeuroScience (Cayman) Ltd (KY) 2018-07-11 EP claimed
EP-2970212-B1 SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS DART NEUROSCIENCE CAYMAN LTD (KY) 2018-04-25 EP claimed
EP-2970212-A1 SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS Dart Neuroscience (Cayman) Ltd (KY) 2016-01-20 EP claimed
US-20160009691-A1 SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS DART NEUROSCIENCE, LLC 2016-01-14 US claimed
WO-2014158998-A1 SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS DART NEUROSCIENCE, LLC (US) 2014-10-02 WO claimed
US-20250122172-A1 SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS DART NEUROSCIENCE LLC 2025-04-17 US disclosed
US-20230075774-A1 SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS DART NEUROSCIENCE LLC (US) 2023-03-09 US disclosed
US-11279691-B2 Substituted pyridine and pyrazine compounds as PDE4 inhibitors DART NEUROSCIENCE LLC (US) 2022-03-22 US disclosed
CN-108299400-B Substituted pyridine and substituted pyrazine compounds as PDE4 inhibitors 达特神经科学(开曼)有限公司 2021-02-19 CN disclosed
EP-3345902-B1 SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS DART NEUROSCIENCE CAYMAN LTD (KY) 2019-10-30 EP disclosed
EP-3345902-B1 SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS DART NEUROSCIENCE CAYMAN LTD (KY) 2019-10-30 EP disclosed
US-20180346448-A1 SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS DART NEUROSCIENCE CAYMAN LTD (KY) 2018-12-06 US disclosed
EP-2970212-B1 SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS DART NEUROSCIENCE CAYMAN LTD (KY) 2018-04-25 EP disclosed
EP-2970212-A1 SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS Dart Neuroscience (Cayman) Ltd (KY) 2016-01-20 EP disclosed
US-20160009691-A1 SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS DART NEUROSCIENCE, LLC 2016-01-14 US disclosed
US-20160009691-A1 SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS DART NEUROSCIENCE, LLC 2016-01-14 US disclosed
US-20160009691-A1 SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS DART NEUROSCIENCE, LLC 2016-01-14 US disclosed
WO-2014158998-A1 SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS DART NEUROSCIENCE, LLC (US) 2014-10-02 WO disclosed
WO-2014158998-A1 SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS DART NEUROSCIENCE, LLC (US) 2014-10-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180346448-A1 SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS PDE4A, PDE4B, PDE4D HDAC1 992/4885HDAC6 1361/4885CTSA 1949/4885
US-20250122172-A1 SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS PDE4A, PDE4B, PDE4D HDAC1 992/4885HDAC6 1361/4885CTSA 1949/4885
US-20160009691-A1 SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS PDE4A, PDE4B, PDE4D HDAC1 1015/4885HDAC6 1400/4885CTSA 1882/4885
US-20230075774-A1 SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS PDE4A, PDE4B, PDE4D HDAC1 992/4885HDAC6 1361/4885CTSA 1949/4885
US-11279691-B2 Substituted pyridine and pyrazine compounds as PDE4 inhibitors PDE4A, PDE4B, PDE4D HDAC1 1015/4885HDAC6 1400/4885CTSA 1882/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.